A5033099455- Bladder and Urothelial Cancer Treatments
- Organ Donation and Transplantation
- Renal and Vascular Pathologies
- Cancer Immunotherapy and Biomarkers
- Renal Transplantation Outcomes and Treatments
- Urinary and Genital Oncology Studies
- Sexual function and dysfunction studies
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Organ Transplantation Techniques and Outcomes
- Cancer, Stress, Anesthesia, and Immune Response
- Hormonal and reproductive studies
- Kidney Stones and Urolithiasis Treatments
- Pediatric Urology and Nephrology Studies
- Urological Disorders and Treatments
- Renal cell carcinoma treatment
- Sexual Differentiation and Disorders
- Sexuality, Behavior, and Technology
- MicroRNA in disease regulation
- Ureteral procedures and complications
- Extracellular vesicles in disease
- Renal and related cancers
- Organ and Tissue Transplantation Research
- Genital Health and Disease
- Viral-associated cancers and disorders
Bellvitge University Hospital
2016-2025
Universitat de Barcelona
2012-2025
Institut Català de la Salut
2024
Institut d'Investigació Biomédica de Bellvitge
2018-2019
Manufacturas Serviplast (Spain)
2017
Puigvert Foundation
2012
Although it is specific for prostatic tissue, serum prostate-specific antigen (PSA) screening has resulted in an over-diagnosis of prostate cancer (PCa) and many unnecessary biopsies benign disease due to a well-documented low specificity, thus improvement required. We profiled the expression level miRNAs contained semen exosomes from men with moderately increased PSA levels assess their usefulness, either alone or addition marker, as non-invasive biomarkers, early efficient diagnosis...
Abstract Purpose: The combination of radiation and immunotherapy potentiated antitumor activity in preclinical models. purpose this study is to explore the feasibility, safety, efficacy a bladder-preserving approach, including dual immune checkpoint blockade radiotherapy, patients with muscle-invasive bladder cancer (MIBC). Patients Methods: localized MIBC underwent transurethral resection, followed by durvalumab (1,500 mg) plus tremelimumab (75 every 4 weeks for three doses concurrent...
<p>Supplementary Figure 2. Analysis of potential prognostic factors. A) Forest plot for Bladder preserved free tumor survival (BPFS), defined as the time from start immunotherapy to either date cystectomy, or recurrence muscle-invasive bladder carcinoma distant recurrence, death. B) Distant metastasis-free (DMFS), therapy C) Overall (OS). Hazard ratios obtained a Cox univariate analysis are shown below each Kaplan meier graph depict correlation molecular, and clinical characteristics.</p>
<p>Supplementary Figure 4. Phenotype profiling of immune populations by flow cytometry in patients treated with standard care (SOC), radiotherapy and chemotherapy plus cystectomy. A) Percentage cellsRadar plots, showing the mean amount cells/mL blood, for each population grouped treatment cohort at baseline (Basal), one week (1W), end (EOT) 1-3 months after EOT (ATm). B) cells within CD8 or CD4 T (mean+SE). Statistics comparisons between timepoint basal levels (U Mann-Whitney test, *...
<p>Supplementary Figure 1. Competing risk analysis. A) analysis showing the cumulative expected incidence of NMIBC in presence following competing events: Death, Cystectomy and Muscle Invasive Bladder Cancer. B) MIBC Death Cystectomy. C) distant metastasis Death.</p>
<p>Supplementary Figure 5. Measurement of soluble inflammatory mediators in peripheral blood by multiplex assay. Heatmap showing changes the expression each biomarker standard care (SOC) cohort. Values have been normalized against basal levels and between analytes.</p>
<p>Supplementary Figure 3. Efficacy time-to-event endpoints in patients stratified according to PD-L1 expression. A) Bladder preserved free of tumor survival (BPFS). B) Disease-free (DFS). C) Relapse-free (RFS). Log rank p-values enclosed each panel.</p>
<div>AbstractPurpose:<p>The combination of radiation and immunotherapy potentiated antitumor activity in preclinical models. The purpose this study is to explore the feasibility, safety, efficacy a bladder-preserving approach, including dual immune checkpoint blockade radiotherapy, patients with muscle-invasive bladder cancer (MIBC).</p>Patients Methods:<p>Patients localized MIBC underwent transurethral resection, followed by durvalumab (1,500 mg) plus tremelimumab...
<p>Supplementary Figure 4. Phenotype profiling of immune populations by flow cytometry in patients treated with standard care (SOC), radiotherapy and chemotherapy plus cystectomy. A) Percentage cellsRadar plots, showing the mean amount cells/mL blood, for each population grouped treatment cohort at baseline (Basal), one week (1W), end (EOT) 1-3 months after EOT (ATm). B) cells within CD8 or CD4 T (mean+SE). Statistics comparisons between timepoint basal levels (U Mann-Whitney test, *...
<p>Supplementary Figure 1. Competing risk analysis. A) analysis showing the cumulative expected incidence of NMIBC in presence following competing events: Death, Cystectomy and Muscle Invasive Bladder Cancer. B) MIBC Death Cystectomy. C) distant metastasis Death.</p>
<p>Supplementary Figure 3. Efficacy time-to-event endpoints in patients stratified according to PD-L1 expression. A) Bladder preserved free of tumor survival (BPFS). B) Disease-free (DFS). C) Relapse-free (RFS). Log rank p-values enclosed each panel.</p>
<p>Supplementary Figure 5. Measurement of soluble inflammatory mediators in peripheral blood by multiplex assay. Heatmap showing changes the expression each biomarker standard care (SOC) cohort. Values have been normalized against basal levels and between analytes.</p>
<p>Supplementary Figure 2. Analysis of potential prognostic factors. A) Forest plot for Bladder preserved free tumor survival (BPFS), defined as the time from start immunotherapy to either date cystectomy, or recurrence muscle-invasive bladder carcinoma distant recurrence, death. B) Distant metastasis-free (DMFS), therapy C) Overall (OS). Hazard ratios obtained a Cox univariate analysis are shown below each Kaplan meier graph depict correlation molecular, and clinical characteristics.</p>
Objective To compare functional and surgical outcomes of robot‐assisted ileal ureter replacement (RAIUR) vs kidney autotransplantation (RAKAT). Patients Methods This was a retrospective analysis patients who underwent RAIUR or RAKAT for long ureteric strictures at eight European tertiary centres (2017–2024). Primary endpoints were maintenance estimated glomerular filtration rate (eGFR) postoperative complications within 30 days surgery, described using the Clavien–Dindo classification....